首页|重构本草——泽泻

重构本草——泽泻

扫码查看
通过古籍文献调研、中医药现代研究成果的梳理,结合中医临床及中药学等学科领域内知名专家学者的认识及应用经验,归纳出泽泻:功效主要为利水渗湿,泄热,化浊降脂.症靶为眩晕和水肿.标靶为高血脂和高血压.现代药理研究发现,泽泻及其有效成分具有利尿与抗利尿、降低血压和血脂等作用.本品有一定的肝肾毒性,使用盐制品可降低毒性,或注意服药剂量与用药周期保证用药安全.临床使用剂量为10~30g,内服时当根据不同疾病,或同一疾病的不同阶段进行辨证使用,并积极探索泽泻用量与症靶、标靶的量效关系构建.
Reconstruction of Chinese materia medica-oriental waterplantain rhizome
Through the investigation of ancient books and the sorting of the modern research achievements of traditional Chinese medicine,combined with the understanding and application experience of well-known experts and scholars in desciplinary fields such as traditional Chinese medicine clinical medicine and science of Chinese materia medica,it is concluded that oriental waterplantain rhizome mainly has the effects of diuresis and diffusing dampness,clearing heat,and resolving turbidity and reducing blood lipid concentrations.The symptom targets are dizziness and edema.The biochemical indicator targets are hyperlipidemia and hypertension.Modern pharmacological studies have found that oriental waterplantain rhizome and its active ingredients have the effects of diuresis and antidiuresis,lowering blood pressure,and reducing the levels of blood lipids.Oriental waterplantain rhizome has cerain liver and kidney toxicity.The use of its salt products can reduce toxicity,or when using this medicine,attention should be paid to the medication dosage and treatment cycle to ensure medication safety.The clinical dosage is 10-30g.When taken orally,it should be used dialectically according to different diseases or different stages of the same disease,and the construction of dose-effect relationship between the dosage of oriental waterplantain rhizome and the symptom target and biochemical indicator target should be explored actively.

oriental waterplantain rhizomesymptom targetbiochemical indicator targetreconstruction of Chinese materia medicaclinical verification

李梦甜、乔丽萍、张伟、孙郡、王昭博、王佳、高琳

展开 >

中国中医科学院广安门医院代谢病研究所,北京 100053

甘肃中医药大学基础医学院,兰州 730000

长春中医药大学,长春 130117

中国中医科学院广安门医院综合科,北京 100053

展开 >

泽泻 症靶 标靶 重构本草 临床回归

2024

长春中医药大学学报
长春中医药大学

长春中医药大学学报

CSTPCD
影响因子:0.916
ISSN:1007-4813
年,卷(期):2024.40(6)